BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares.

Detailed price information for Henry Schein Inc (HSIC-Q) from The Globe and Mail including charting and trades.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amgen (AMGN – Research Report) and Align Tech (ALGN – Research Report). Stay Ahead of the Mar ...

GRAIL's groundbreaking Galleri test, detecting 50+ cancers, FDA status, and strategic growth make it a top investment with ...

In the wake of the stock market’s selloff, 125 of the 855 US-listed stocks Morningstar covers now sit at 5 stars, signaling ...

Buying $1000 In DGX: If an investor had bought $1000 of DGX stock 5 years ago, it would be worth $963,529.41 today based on a ...

According to Benzinga Pro, Quest Diagnostics's peer group average for short interest as a percentage of float is 9.65%, which means the company has less short interest than most of its peers. Did you ...

This was the stock's second consecutive day of losses.

The perception of Synopsys by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and ...

In a report released today, David Adlington from J.P. Morgan maintained a Sell rating on Fresenius Medical Care AG & Co. KGaA (0H9X – ...

There was a mix-up regarding my appointment for blood testing this morning. I arrived on time for my appointment but the kiosk indicated no appointment scheduled. It was 10 minutes to 12 (office ...

Our data suggest Mr Trump has a net negative approval rating in all six swing states he flipped away from Joe Biden in November’s presidential election (Arizona, Nevada, Georgia, Pennsylvania ...